289 related articles for article (PubMed ID: 23725275)
21. [Immunotherapy targeting cancer stem cells].
Kawakami Y; Matsushita M; Ueda R; Tsukamoto N; Ohta S
Nihon Rinsho; 2012 Dec; 70(12):2142-6. PubMed ID: 23259387
[TBL] [Abstract][Full Text] [Related]
22. [Future prospects for specific immunotherapy].
Sugaya M; Takenoyama M; Yasumoto K
Nihon Rinsho; 2002 May; 60 Suppl 5():609-13. PubMed ID: 12101747
[No Abstract] [Full Text] [Related]
23. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
24. [Development for a novel cancer vaccine].
Tsunoda T
Gan To Kagaku Ryoho; 2004 Dec; 31(13):2095-9. PubMed ID: 15628750
[TBL] [Abstract][Full Text] [Related]
25. Tumor specific CD8+ T cells in patients with lung cancer and healthy individuals.
Karanikas V; Germenis A
J BUON; 2009 Sep; 14 Suppl 1():S153-7. PubMed ID: 19785058
[TBL] [Abstract][Full Text] [Related]
26. [Immune therapy against hepatocellular carcinoma using gene-modified tumor cells].
Miyagi T; Tatsumi T; Hayashi N
Nihon Rinsho; 2001 Oct; 59 Suppl 6():688-92. PubMed ID: 11762038
[No Abstract] [Full Text] [Related]
27. Immune response against tumor antigens expressed on human cancer stem-like cells/tumor-initiating cells.
Hirohashi Y; Torigoe T; Inoda S; Takahashi A; Morita R; Nishizawa S; Tamura Y; Suzuki H; Toyota M; Sato N
Immunotherapy; 2010 Mar; 2(2):201-11. PubMed ID: 20635928
[TBL] [Abstract][Full Text] [Related]
28. Drug-mediated and cellular immunotherapy in multiple myeloma.
Ritchie DS; Quach H; Fielding K; Neeson P
Immunotherapy; 2010 Mar; 2(2):243-55. PubMed ID: 20635931
[TBL] [Abstract][Full Text] [Related]
29. Genetically modified tumour vaccines--where we are today.
Nawrocki S; Mackiewicz A
Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
[TBL] [Abstract][Full Text] [Related]
30. [Cellular immunotherapy for hematological malignancies].
Yasukawa M
Rinsho Ketsueki; 2008 Oct; 49(10):1460-71. PubMed ID: 18833930
[No Abstract] [Full Text] [Related]
31. [Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens].
Prikler L; Scandella E; Men Y; Engeler DS; Diener PA; Gillessen S; Ludewig B; Schmid HP
Aktuelle Urol; 2004 Aug; 35(4):326-30. PubMed ID: 15459874
[TBL] [Abstract][Full Text] [Related]
32. Cancer immunotherapy by local transfer of autologous T lymphocytes cultured with T cell growth factor and autologous tumor extract: a clinical trial.
Kan N; Ohgaki K; Yamasaki N; Hori T; Nakayama N; Nio Y; Inamoto T; Hikasa Y
Nihon Geka Hokan; 1983 Nov; 52(6):841-53. PubMed ID: 6380446
[No Abstract] [Full Text] [Related]
33. Immunotherapy of hematological malignancies using dendritic cells.
Van de Velde AL; Berneman ZN; Van Tendeloo VF
Bull Cancer; 2008 Mar; 95(3):320-6. PubMed ID: 18390412
[TBL] [Abstract][Full Text] [Related]
34. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
35. Future of immunotherapy drug combinations and biomarkers.
Schmidt C
J Natl Cancer Inst; 2012 Mar; 104(6):434-9. PubMed ID: 22402694
[No Abstract] [Full Text] [Related]
36. Peptide vaccines for patients with acute myeloid leukemia.
Schmitt M; Casalegno-Garduño R; Xu X; Schmitt A
Expert Rev Vaccines; 2009 Oct; 8(10):1415-25. PubMed ID: 19803762
[TBL] [Abstract][Full Text] [Related]
37. Cancer vaccines: pessimism in check.
Mocellin S; Mandruzzato S; Bronte V; Marincola FM
Nat Med; 2004 Dec; 10(12):1278-9; author reply 1279-80. PubMed ID: 15580242
[No Abstract] [Full Text] [Related]
38. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
39. Advances in cancer immunotherapy.
Ockert D; Schmitz M; Hampl M; Rieber EP
Immunol Today; 1999 Feb; 20(2):63-5. PubMed ID: 10098323
[No Abstract] [Full Text] [Related]
40. Immune monitoring in cancer immunotherapy.
Romero P; Pittet MJ; Valmori D; Speiser DE; Cerundolo V; Liénard D; Lejeune F; Cerottini JC
Ernst Schering Res Found Workshop; 2000; (30):75-97. PubMed ID: 10943317
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
